EcoDrugPlus

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSMMDG00005005658
Gene Symbol: NT5E
1 Cross references
178 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSMMDG00005023905
Gene Symbol: HTR2B
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSMMDG00005002037
Gene Symbol: HTR2CL1
1 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSMMDG00005010883
Gene Symbol: HTR5AB
1 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSMMDG00005006266
Gene Symbol: HTR1A
3 Cross references
104 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta

Ensembl ID : ENSMMDG00005003967
Gene Symbol: LOC115369021
3 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSMMDG00005006213
Gene Symbol: HTR1B
3 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSMMDG00005013962
Gene Symbol: HTR1B
3 Cross references
184 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSMMDG00005015096
Gene Symbol: HTR1E
3 Cross references
148 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSMMDG00005020097
Gene Symbol: HTR1F
3 Cross references
142 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSMMDG00005007992
Gene Symbol: HTR2A
1 Cross references
219 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMMDG00005014807
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).